Eli Lilly

Diversified pharma

LLY · NYSE · United States

Share price · LLY

$1382.75+157.02 (+12.81%) 3M

close as of 2026-11-18 · 24h delayed · vol 2.9M (1.0x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when LLY's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 9 Nov 2026+4.3%
  2. 30 Oct 2026+3.2%
  3. 29 Oct 2026+6.6%
  4. 5 Aug 2026+4.9%
  5. 30 Jul 2026-4.5%
  6. 26 Jun 2026+7.1%
  7. 30 Apr 2026+9.8%
  8. 17 Mar 2026-5.9%
  9. 5 Feb 2026-7.8%
  10. 4 Feb 2026+10.3%

Share of unusual movement by asset

For each asset, the share of LLY's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
orforglipron (Foundayo)
events and moves
2523%
Donanemab (Kisunla)
events and moves
156%
Pirtobrutinib
events and moves
154%
lebrikizumab (Ebglyss)
events and moves
113%
mirikizumab (Omvoh)
events and moves
131%
retatrutide
events and moves
131%
Imlunestrant (Inluriyo)
events and moves
111%
Tirzepatide (Mounjaro) (Mounjaro)
events and moves
7shown from 8 days
ixekizumab (Taltz)
events and moves
7shown from 8 days
Abemaciclib (Verzenio)
events and moves
7shown from 8 days
mazdutide
events and moves
7shown from 8 days
Tirzepatide (Zepbound) (Zepbound)
events and moves
7shown from 8 days
Insulin Efsitora Alfa (Onswik)
events and moves
6shown from 8 days
baricitinib (Olumiant)
events and moves
5shown from 8 days
eloralintide
events and moves
3shown from 8 days
Selpercatinib (Retevmo)
events and moves
3shown from 8 days
Sofetabart mipitecan
events and moves
3shown from 8 days
bimagrumab
events and moves
2shown from 8 days
EMP-01
events and moves
2shown from 8 days
Olomorasib
events and moves
2shown from 8 days
Lepodisiran
events and moves
1shown from 8 days
Muvalaplin
events and moves
1shown from 8 days
VERVE-102
events and moves
1shown from 8 days
BPL-003 (mebufotenin benzoate)
events and moves
1shown from 8 days
VLS-01
events and moves
1shown from 8 days
Assets with fewer than 8 event days, together—7%
Other company news (earnings, financing, releases naming no asset)—30%
Sessions with no dated event—23%

Assets

(73 total)
73Total Assets
30Approved
11Phase 3 / Filed
32Phase 1–2 / Early
55Diseases
Quick filter:
Showing 73 of 73 assets
Target & Modality
Abemaciclib(Verzenio)
Approved
CDK4 and CDK6Small molecule
Breast CancerGlioma
HR+/HER2- Metastatic Breast Cancer
baricitinib(Olumiant)
Approved
JAK · JAK1/2Small molecule
Atopic DermatitisRheumatoid ArthritisAlopecia AreataCOVID-19
Approved
EGFRMonoclonal antibody
Head and Neck Squamous Cell CarcinomaColorectal Cancer
Metastatic Colorectal Cancer
Donanemab(Kisunla)
Approved
Amyloid-beta (monoclonal antibody)Monoclonal antibody
Alzheimer's Disease
dulaglutide(Trulicity)
Approved
GLP-1 receptorPeptide
Type 2 DiabetesAtherosclerotic Cardiovascular Disease
Duloxetine(Cymbalta)
Approved
Serotonin/norepinephrine transporter · Serotonin and norepinephrine transporters (SERT/NET)Small molecule
Major Depressive DisorderDiabetic Peripheral Neuropathic PainFibromyalgiaGeneralized Anxiety Disorder
Empagliflozin(Jardiance)
Approved
SGLT2Small molecule
Type 2 DiabetesHeart FailureChronic Kidney DiseaseAtherosclerotic Cardiovascular Disease
Approved
CGRP ligandMonoclonal antibody
Migraine
Approved
ribonucleotide reductase / DNA polymerase (dCTP competition)Small molecule
Non-Small Cell Lung CancerBreast CancerOvarian CancerPancreatic Ductal AdenocarcinomaPancreatic Cancer
HR+/HER2- Metastatic Breast Cancer
Imlunestrant(Inluriyo)
Approved
Estrogen receptorSmall molecule
Breast Cancer
HR+/HER2- Metastatic Breast Cancer
Approved
Insulin receptor (basal)Protein / enzyme therapeutic
Type 2 Diabetes
Approved
Insulin receptor (basal)Peptide
Type 2 DiabetesType 1 Diabetes
Approved
Insulin
Type 1 Diabetes
Approved
Insulin receptorPeptide
Type 2 DiabetesType 1 Diabetes
Approved
Insulin receptorPeptide
Type 2 DiabetesType 1 Diabetes

Discontinued programmes (4)

Development of these assets stopped. Each page states the sourced discontinuation and keeps the trials as evidence history.

Upcoming events

(103 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (4)
November 2026 (3)
retatrutidePhase 3Obesity
Est. primary completion 2026-11 · NCT06662383 · CT.gov ↗
What to watch
Tirzepatide (Zepbound)Phase 3Type 1 Diabetes, Obesity, Overweight
Est. primary completion 2026-11 · NCT06914895 · CT.gov ↗
What to watch
Tirzepatide (Zepbound)Phase 3Type 1 Diabetes, Obesity, Overweight
Est. primary completion 2026-11 · NCT06962280 · CT.gov ↗
What to watch
December 2026 (1)
mazdutidePhase 3Overweight, Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD)
Est. primary completion 2026-12-31 · NCT06884293 · CT.gov ↗
What to watch
2027 (42)
February 2027 (3)
Est. primary completion 2027-02 · NCT06413706 · CT.gov ↗
What to watch
BrenipatidePhase 2Smoking
Est. primary completion 2027-02 · NCT07223840 · CT.gov ↗
What to watch
orforglipron · FoundayoPhase 3Obesity, Overweight
Est. primary completion 2027-02 · NCT06672549 · CT.gov ↗
What to watch
March 2027 (2)
macupatide + eloralintidePhase 2Obesity, Overweight, Diabetes Mellitus, Type 2
Est. primary completion 2027-03 · NCT07215559 · CT.gov ↗
What to watch
SolbinsiranPhase 2Severe Hypertriglyceridemia
Est. primary completion 2027-03 · NCT07269210 · CT.gov ↗
What to watch
April 2027 (6)
Cetuximab + Olomorasib + pemetrexed · AlimtaPhase 1/2Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Endometrial Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms …
Est. primary completion 2027-04 · NCT04956640 · CT.gov ↗
What to watch
LY4065967Phase 2Osteoarthritis, Knee, Diabetic Neuropathic Pain, Chronic Low-back Pain
Est. primary completion 2027-04 · NCT05986292 · CT.gov ↗
What to watch
LY4065967Phase 2Chronic Pain, Low Back Pain
Est. primary completion 2027-04 · NCT07641504 · CT.gov ↗
What to watch
LY4065967Phase 2Osteoarthritis, Knee, Chronic Pain
Est. primary completion 2027-04 · NCT07641517 · CT.gov ↗
What to watch
Empagliflozin · JardiancePhase 3Chronic Kidney Disease
Est. primary completion 2027-04-16 · NCT07107945 · CT.gov ↗
What to watch
lebrikizumab · EbglyssPhase 3Dermatitis, Atopic, Eczema
Est. primary completion 2027-04-25 · NCT06526182 · CT.gov ↗
What to watch
May 2027 (5)
mirikizumab · Omvoh + ZotemtegrastPhase 2Ulcerative Colitis
Est. primary completion 2027-05 · NCT07186101 · CT.gov ↗
What to watch
Ramucirumab + Abemaciclib · VerzenioPhase 2Neoplasms, Child, Adolescent
Est. primary completion 2027-05 · NCT05999994 · CT.gov ↗
What to watch
orforglipron · FoundayoPhase 3Diabetes Mellitus, Type 2, Diabetes Melletus, Glucose Metabolism Disorders, Metabolic Disorders, Nutritional and Metabolic Diseases …
Est. primary completion 2027-05 · NCT07613307 · CT.gov ↗
What to watch
lebrikizumab · EbglyssPhase 3Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Est. primary completion 2027-05 · NCT06338995 · CT.gov ↗
What to watch
mazdutidePhase 3Sleep Apnea, Obstructive, Obesity
Est. primary completion 2027-05-07 · NCT06931028 · CT.gov ↗
What to watch
June 2027 (1)
retatrutidePhase 3Obesity, Overweight
Est. primary completion 2027-06 · NCT07232719 · CT.gov ↗
What to watch
July 2027 (2)
BrenipatidePhase 2Irritable Bowel Syndrome, Constipation
Est. primary completion 2027-07 · NCT07545772 · CT.gov ↗
What to watch
LY4065967Phase 2Diabetic Peripheral Neuropathic Pain
Est. primary completion 2027-07 · NCT07285018 · CT.gov ↗
What to watch
August 2027 (3)
orforglipron · FoundayoPhase 3Obesity, Overweight
Est. primary completion 2027-08 · NCT06972459 · CT.gov ↗
What to watch
orforglipron · FoundayoPhase 3Obesity, Overweight, Type 2 Diabetes
Est. primary completion 2027-08 · NCT06972472 · CT.gov ↗
What to watch
orforglipron · FoundayoPhase 3Obesity, Overweight, Type 2 Diabetes
Est. primary completion 2027-08 · NCT06993792 · CT.gov ↗
What to watch
September 2027 (7)
Est. primary completion 2027-09 · NCT06143956 · CT.gov ↗
What to watch
macupatide + eloralintidePhase 2Overweight, Obesity
Est. primary completion 2027-09 · NCT07589608 · CT.gov ↗
What to watch
BrenipatidePhase 2Irritable Bowel Syndrome, Diarrhea
Est. primary completion 2027-09 · NCT07545759 · CT.gov ↗
What to watch
orforglipron · FoundayoPhase 3Hypertension
Est. primary completion 2027-09 · NCT06948422 · CT.gov ↗
What to watch
orforglipron · FoundayoPhase 3Hypertension, Overweight or Obesity
Est. primary completion 2027-09 · NCT06948435 · CT.gov ↗
What to watch
orforglipron · FoundayoPhase 3Hypertension
Est. primary completion 2027-09 · NCT06952530 · CT.gov ↗
What to watch
retatrutidePhase 3Obesity, Overweight, Chronic Low Back Pain (CLBP)
Est. primary completion 2027-09 · NCT07035093 · CT.gov ↗
What to watch
October 2027 (4)
Imlunestrant · InluriyoPhase 3Breast Neoplasms
Est. primary completion 2027-10 · NCT05514054 · CT.gov ↗
What to watch
Tirzepatide (Zepbound)Phase 3Obesity, Overweight
Est. primary completion 2027-10 · NCT05556512 · CT.gov ↗
What to watch
Tirzepatide (Zepbound)Phase 3Obesity, Weight Gain
Est. primary completion 2027-10 · NCT06439277 · CT.gov ↗
What to watch
mazdutidePhase 3Adolescents With Obesity or Overweight With Weight-Related Comorbidities
Est. primary completion 2027-10-31 · NCT07255209 · CT.gov ↗
What to watch
November 2027 (4)
BrenipatidePhase 2Bipolar Disorder
Est. primary completion 2027-11 · NCT07286175 · CT.gov ↗
What to watch
BrenipatidePhase 2Schizophrenia
Est. primary completion 2027-11 · NCT07410507 · CT.gov ↗
What to watch
Donanemab · KisunlaPhase 3Alzheimer Disease
Est. primary completion 2027-11 · NCT05026866 · CT.gov ↗
What to watch
OlomorasibPhase 3Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
Est. primary completion 2027-11 · NCT06119581 · CT.gov ↗
What to watch
December 2027 (5)
Abemaciclib · Verzenio + TersolisibPhase 2Breast Neoplasms
Est. primary completion 2027-12 · NCT07935317 · CT.gov ↗
What to watch
lebrikizumab · EbglyssPhase 3Atopic Dermatitis, Eczema
Est. primary completion 2027-12 · NCT05735483 · CT.gov ↗
What to watch
mirikizumab · OmvohPhase 3Crohn's Disease
Est. primary completion 2027-12 · NCT05509777 · CT.gov ↗
What to watch
orforglipron · FoundayoPhase 3Obesity, Overweight
Est. primary completion 2027-12 · NCT06672939 · CT.gov ↗
What to watch
dulaglutide · TrulicityPhase 3Type 2 Diabetes
Est. primary completion 2027-12 · NCT06739122 · CT.gov ↗
What to watch
2028 (32)
January 2028 (1)
eloralintidePhase 3Overweight, Obesity
Est. primary completion 2028-01 · NCT07282600 · CT.gov ↗
What to watch
February 2028 (3)
PirtobrutinibPhase 1/2Immune Thrombocytopenia (ITP)
Est. primary completion 2028-02 · NCT06721013 · CT.gov ↗
What to watch
lebrikizumab · EbglyssPhase 3Atopic Dermatitis
Est. primary completion 2028-02 · NCT07873801 · CT.gov ↗
What to watch
BrenipatidePhase 3Depressive Disorder, Major
Est. primary completion 2028-02 · NCT07412756 · CT.gov ↗
What to watch
March 2028 (7)
BrenipatidePhase 2Opioid Use Disorder
Est. primary completion 2028-03 · NCT07420283 · CT.gov ↗
What to watch
orforglipron · FoundayoPhase 3Obesity, Overweight
Est. primary completion 2028-03 · NCT07790861 · CT.gov ↗
What to watch
baricitinib · OlumiantPhase 3Areata Alopecia, Alopecia, Hypotrichosis, Hair Diseases, Skin Diseases, Pathological Conditions, Anatomical
Est. primary completion 2028-03 · NCT05723198 · CT.gov ↗
What to watch
orforglipron · FoundayoPhase 3Urinary Incontinence,Stress
Est. primary completion 2028-03 · NCT07202884 · CT.gov ↗
What to watch
eloralintidePhase 3Obesity, Overweight
Est. primary completion 2028-03 · NCT07321886 · CT.gov ↗
What to watch
eloralintidePhase 3Osteoarthritis, Overweight or Obesity
Est. primary completion 2028-03 · NCT07353931 · CT.gov ↗
What to watch
eloralintidePhase 3Sleep Apnea, Obstructive, Obesity, Overweight
Est. primary completion 2028-03 · NCT07369011 · CT.gov ↗
What to watch
April 2028 (6)
BrenipatidePhase 2Asthma
Est. primary completion 2028-04 · NCT07219173 · CT.gov ↗
What to watch
orforglipron · FoundayoPhase 3Osteoarthritis
Est. primary completion 2028-04 · NCT07153471 · CT.gov ↗
What to watch
retatrutidePhase 3Obesity
Est. primary completion 2028-04 · NCT06859268 · CT.gov ↗
What to watch
mirikizumab · Omvoh + Tirzepatide (Zepbound)Phase 3Ulcerative Colitis, Obesity or Overweight
Est. primary completion 2028-04 · NCT06937086 · CT.gov ↗
What to watch
BrenipatidePhase 3Alcohol Use Disorder
Est. primary completion 2028-04 · NCT07219953 · CT.gov ↗
What to watch
BrenipatidePhase 3Alcohol Use Disorder
Est. primary completion 2028-04 · NCT07219966 · CT.gov ↗
What to watch
May 2028 (4)
BrenipatidePhase 2Major Depressive Disorder
Est. primary completion 2028-05 · NCT07928245 · CT.gov ↗
What to watch
BrenipatidePhase 2Pulmonary Disease, Chronic Obstructive
Est. primary completion 2028-05 · NCT07759245 · CT.gov ↗
What to watch
Donanemab · KisunlaPhase 3Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies …
Est. primary completion 2028-05 · NCT05508789 · CT.gov ↗
What to watch
mirikizumab · Omvoh + Tirzepatide (Zepbound)Phase 3Crohn's Disease, Obesity or Overweight
Est. primary completion 2028-05 · NCT06937099 · CT.gov ↗
What to watch
June 2028 (2)
orforglipron · FoundayoPhase 3Peripheral Arterial Disease
Est. primary completion 2028-06 · NCT07223593 · CT.gov ↗
What to watch
eloralintidePhase 3Overweight, Obesity
Est. primary completion 2028-06 · NCT07392190 · CT.gov ↗
What to watch
July 2028 (1)
baricitinib · OlumiantPhase 3Diabetes Mellitus, Type 1
Est. primary completion 2028-07 · NCT07222332 · CT.gov ↗
What to watch
August 2028 (3)
Donanemab · KisunlaPhase 2Cognitive Dysfunction, Lewy Body Disease, Synucleinopathies, Amyloid
Est. primary completion 2028-08 · NCT07589595 · CT.gov ↗
What to watch
VERVE-102Phase 2Atherosclerosis, Cardiovascular Disease, Hypercholesterolemia
Est. primary completion 2028-08 · NCT07839936 · CT.gov ↗
What to watch
lebrikizumab · EbglyssPhase 3Nummular Eczema
Est. primary completion 2028-08 · NCT07542483 · CT.gov ↗
What to watch
September 2028 (1)
ZotemtegrastPhase 2Inflammatory Bowel Diseases, Crohn's Disease
Est. primary completion 2028-09 · NCT06226883 · CT.gov ↗
What to watch
October 2028 (1)
retatrutidePhase 3Obesity, Overweight
Est. primary completion 2028-10 · NCT07357415 · CT.gov ↗
What to watch
November 2028 (2)
Cetuximab + OlomorasibPhase 2Colorectal Neoplasms
Est. primary completion 2028-11 · NCT07814417 · CT.gov ↗
What to watch
Sofetabart mipitecanPhase 3Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms, Neoplasm Metastasis
Est. primary completion 2028-11 · NCT07213804 · CT.gov ↗
What to watch
December 2028 (1)
BrenipatidePhase 3Depressive Disorder, Major
Est. primary completion 2028-12 · NCT07775300 · CT.gov ↗
What to watch
2029 (14)
January 2029 (1)
Imlunestrant · InluriyoPhase 2Breast Neoplasms
Est. primary completion 2029-01 · NCT07287098 · CT.gov ↗
What to watch
February 2029 (1)
retatrutidePhase 3Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
Est. primary completion 2029-02 · NCT06383390 · CT.gov ↗
What to watch
March 2029 (1)
LepodisiranPhase 3Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
Est. primary completion 2029-03 · NCT06292013 · CT.gov ↗
What to watch
April 2029 (1)
RemternetugPhase 3Alzheimer's Disease
Est. primary completion 2029-04 · NCT06653153 · CT.gov ↗
What to watch
May 2029 (2)
OlomorasibPhase 3Carcinoma, Non-Small-Cell Lung
Est. primary completion 2029-05 · NCT06890598 · CT.gov ↗
What to watch
TersolisibPhase 3Breast Neoplasms, Neoplasm Metastasis
Est. primary completion 2029-05 · NCT07174336 · CT.gov ↗
What to watch
July 2029 (1)
bimagrumabPhase 2Heart Failure, Diastolic, Diastolic Heart Failure, Heart Failure, Normal Ejection Fraction, Heart Failure, Preserved Ejection Fraction
Est. primary completion 2029-07 · NCT07920887 · CT.gov ↗
What to watch
August 2029 (1)
orforglipron · FoundayoPhase 3Overweight, Prediabetic State, Prehypertension, Obesity, Abdominal
Est. primary completion 2029-08 · NCT07794579 · CT.gov ↗
What to watch
September 2029 (1)
Donanemab · KisunlaPhase 3Alzheimer Disease, Dementia, Plaque, Amyloid
Est. primary completion 2029-09 · NCT07602582 · CT.gov ↗
What to watch
October 2029 (2)
Est. primary completion 2029-10 · NCT07881432 · CT.gov ↗
What to watch
eloralintide + Tirzepatide (Zepbound)Phase 3Obesity, Overweight, Diabetes Mellitus, Type 2
Est. primary completion 2029-10 · NCT07881458 · CT.gov ↗
What to watch
November 2029 (1)
eloralintidePhase 3Obesity, Overweight, Cardiovascular Diseases, Diabetes Mellitus, Type 2
Est. primary completion 2029-11 · NCT07900633 · CT.gov ↗
What to watch
December 2029 (2)
LepodisiranPhase 3Atherosclerosis, Cardiovascular Diseases, Lipoprotein(a)
Est. primary completion 2029-12 · NCT07613294 · CT.gov ↗
What to watch
Est. primary completion 2029-12 · NCT07817875 · CT.gov ↗
What to watch
2030 (7)
March 2030 (1)
orforglipron · FoundayoPhase 3Diabetes Mellitus, Type 2
Est. primary completion 2030-03 · NCT07668336 · CT.gov ↗
What to watch
April 2030 (1)
Donanemab · KisunlaPhase 3Alzheimer Disease
Est. primary completion 2030-04 · NCT07571161 · CT.gov ↗
What to watch
May 2030 (1)
PirtobrutinibPhase 2Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, B-cell Lymphoma
Est. primary completion 2030-05 · NCT07162181 · CT.gov ↗
What to watch
June 2030 (1)
ZotemtegrastPhase 2Ulcerative Colitis (UC), Ulcerative Colitis, Active Moderate, Ulcerative Colitis, Active Severe
Est. primary completion 2030-06 · NCT07415044 · CT.gov ↗
What to watch
July 2030 (1)
Abemaciclib · Verzenio + Tersolisib + Imlunestrant · InluriyoPhase 1/2Breast Cancer, Solid Tumors, Adult
Est. primary completion 2030-07 · NCT05768139 · CT.gov ↗
What to watch
August 2030 (1)
Tirzepatide (Mounjaro) + retatrutidePhase 3Metabolic Dysfunction-Associated Steatotic Liver Disease
Est. primary completion 2030-08 · NCT07165028 · CT.gov ↗
What to watch
December 2030 (1)
mirikizumab · OmvohPhase 3Ulcerative Colitis, Ulcerative Colitis Chronic, Inflammatory Bowel Diseases, Crohn's Disease
Est. primary completion 2030-12 · NCT04844606 · CT.gov ↗
What to watch
2031 (4)
March 2031 (1)
MuvalaplinPhase 3Elevated Lp(a), Atherosclerotic Cardiovascular Disease (ASCVD)
Est. primary completion 2031-03 · NCT07157774 · CT.gov ↗
What to watch
July 2031 (2)
baricitinib · OlumiantPhase 3Juvenile Idiopathic Arthritis
Est. primary completion 2031-07 · NCT03773965 · CT.gov ↗
What to watch
baricitinib · OlumiantPhase 3Diabetes Mellitus, Type 1
Est. primary completion 2031-07 · NCT07222137 · CT.gov ↗
What to watch
August 2031 (1)
orforglipron · FoundayoPhase 3Atherosclerosis Cardiovascular Disease, Chronic Kidney Disease
Est. primary completion 2031-08 · NCT07241390 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(40)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

28 October 2026Topline resultretatrutidePhase 3 TRANSCEND-T2D-2 met its primary endpoint versus Ozempic 2 mg
19 October 2026Topline resultmirikizumabPhase 3 SHINE-2 of Omvoh met its primary endpoint in pediatric UC
2 October 2026ApprovalPirtobrutinibFDA approves Jaypirca for previously untreated CLL/SLL
US, FDA · Eli Lilly and Company · Source ↗
30 September 2026Topline resulteloralintidePhase 2b NCT06603571 of eloralintide with and without tirzepatide met its primary and secondary endpoints
Eli Lilly and Company · Source ↗
25 September 2026ApprovalbaricitinibFDA approves Olumiant for adolescents with severe alopecia areata
US, FDA · Eli Lilly and Company · Source ↗
18 September 2026ApprovalImlunestrantFDA approves Inluriyo in combination with Verzenio
US, FDA · Eli Lilly and Company · Source ↗
September 2026ApprovalInsulin Efsitora AlfaFDA approves Onswik for type 2 diabetes
US, FDA · Eli Lilly and Company · Source ↗
September 2026ApprovalPirtobrutinibNMPA approves Jaypirca for CLL/SLL across all lines of therapy in China
CN, NMPA · Innovent Biologics, Inc. · Source ↗
28 August 2026ApprovaltirzepatideFDA approves Mounjaro to reduce cardiovascular risk in type 2 diabetes
US, FDA · Source ↗
27 August 2026ApprovalTirzepatide (Mounjaro)FDA Boxed Warning on Mounjaro (NDA215866)
US, FDA · FDA · Source ↗
5 August 2026WithdrawalLasmiditan (Reyvow)FDA withdraws approval of NDA 211280 (Federal Register 2026-13616)
US, FDA · Source ↗
23 July 2026Topline resultretatrutideTRIUMPH-3 (NCT05882045) Phase 3 met its primary endpoint
Eli Lilly and Company · Source ↗

The 12 most recent of 40 past events are shown.

Financial reports

Quarterly & interim (18)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$24.4B$4.2B$4.9B—$11.4B operating cash flowreport ↗
View 17 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$23.0B$3.8B$8.9B—$10.7B operating cash flowreport ↗
2026-Q1$19.8B$3.5B$5.3B—$5.3B operating cash flowreport ↗
2025-Q4$19.3B$3.8B$7.3B—report ↗
2025-Q3$17.6B$3.5B$9.9B+ $122M short-term inv.—$8.8B operating cash flowreport ↗
2025-Q2$15.6B$3.3B$3.5B+ $170M short-term inv.—$3.1B operating cash flowreport ↗
2025-Q1$12.7B$2.7B$3.2B+ $127M short-term inv.—$1.7B operating cash flowreport ↗
2024-Q4$13.5B$3.0B$3.4B—report ↗
2024-Q3$11.4B$2.7B$3.5B+ $149M short-term inv.—$3.7B operating cash flowreport ↗
2024-Q2$11.3B$2.7B$3.4B+ $140M short-term inv.—$1.5B operating cash flowreport ↗
2024-Q1$8.8B$2.5B$2.5B+ $126M short-term inv.—$1.2B operating cash flowreport ↗
2023-Q3$9.5B$2.4B$2.4B+ $113M short-term inv.$57M$2.2B operating cash flowreport ↗
2023-Q2$8.3B$2.4B$2.7B+ $135M short-term inv.—$632M operating cash flowreport ↗
2023-Q1$7.0B$2.0B$3.5B+ $123M short-term inv.—$1.7B operating cash flowreport ↗
2022-Q3$6.9B$1.8B$2.6B+ $125M short-term inv.—$2.2B operating cash flowreport ↗
2022-Q2$6.5B—$2.6B+ $114M short-term inv.—$821M operating cash flowreport ↗
2022-Q1$7.8B—$2.5B+ $109M short-term inv.—$2.5B operating cash flowreport ↗
2021-Q3$6.8B—$3.8B+ $37M short-term inv.—$1.6B operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$65.2B$13.3B$7.3B—$16.8B operating cash flowreport ↗

For fiscal 2025, Eli Lilly reported revenue of $65,179M, up 45% YoY, with R&D spend of $13,337M, up 21% YoY, and cash and equivalents of $7,268M. The company recorded net income of $20,640M, up 95% YoY.

Management issued 2026 guidance of $80–$83 billion in revenue and non-GAAP EPS of $33.50–$35.00. Recent developments included FDA approval of Kwikpen for tirzepatide and an expanded Jaypirca indication, regulatory submissions for orforglipron in obesity (U.S./Japan) and obesity and type 2 diabetes (EU), positive Phase 3 results for Taltz plus Zepbound, orforglipron after switching from injectable incretins, and retatrutide in knee osteoarthritis, as well as a U.S. government agreement to expand access to obesity medicines.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$45.0B$11.0B$3.4B+ $155M short-term inv.—$8.8B operating cash flowreport ↗
2023-FY$34.1B$9.3B$2.9B+ $109M short-term inv.—$4.2B operating cash flowreport ↗
2022-FY$28.5B$7.2B$2.1B+ $145M short-term inv.—$7.1B operating cash flowreport ↗
2021-FY$28.3B$6.9B$3.8B+ $90M short-term inv.—$7.3B operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 97 sales ($814.5M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-16Alvarez Ralph · directorAward / grant8.673$1431.67$12KForm 4
2026-11-16Fyrwald J Erik · directorAward / grant6.927$1431.67$10KForm 4
2026-11-16LUCIANO JUAN R · directorAward / grant11.118$1431.67$16KForm 4
2026-11-16Sulzberger Gabrielle · directorAward / grant3.463$1431.67$5KForm 4
2026-11-16Hedley Mary Lynne · directorAward / grant167.636$1431.67$240KForm 4
2026-11-16Baicker Katherine · directorAward / grant167.636$1431.67$240KForm 4
2026-11-16Bertozzi Carolyn R · directorAward / grant177.741$1431.67$254KForm 4
2026-11-16JOHNSON KIMBERLY H · directorAward / grant167.636$1431.67$240KForm 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 4,321 reporting institutions held 776.4M shares ($687.2B, 82.5% of shares outstanding).

#InstitutionSharesValue
1LILLY ENDOWMENT INC91,896,978$84.5B
2BlackRock, Inc.66,380,842$61.1B
3VANGUARD CAPITAL MANAGEMENT LLC53,361,774$49.1B
4PNC FINANCIAL SERVICES GROUP, INC.51,328,908$47.2B
5STATE STREET CORP35,610,002$32.8B
6FMR LLC26,341,031$24.2B
7Capital Research Global Investors24,632,647$22.7B
8VANGUARD PORTFOLIO MANAGEMENT LLC20,977,027$19.3B
9GEODE CAPITAL MANAGEMENT, LLC20,191,864$18.5B
10Capital World Investors15,621,813$14.4B
11MORGAN STANLEY15,437,458$14.2B
12WELLINGTON MANAGEMENT GROUP LLP13,427,061$12.3B
13JPMORGAN CHASE & CO13,698,491$12.1B
14BANK OF AMERICA CORP /DE/11,125,832$10.2B
15STATE FARM MUTUAL AUTOMOBILE INSURANCE CO10,759,188$9.9B